

### Amendments to the Claims

The following listing of the claims replaces all prior listings.

1. (Currently amended) A method for treating a subject having nephropathy comprising:  
treating nephropathy by administering to an individual in need of such treatment an effective amount of a GLP-1, an analog ~~an agonist, analog,~~ or derivative ~~thereof~~ thereof, having at least ~~70%~~ 90% amino acid sequence homology to GLP-1. ~~and having at least one action of GLP-1~~
2. (Previously Presented) The method of claim 1 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO: 1.
- 3-6. (Canceled)
7. (Currently amended) The method of claim ~~[[I]]~~ 1 wherein the compound is administered parenterally.
8. (Currently amended) The method of claim 4 wherein the compound is administered intravenously in a dose of ~~from about~~ 0.1 pmol/kg/min ~~up to about~~ 10 pmol/kg/min.
9. (Currently amended) The method of claim 1 wherein the compound is administered subcutaneously in a dose of ~~from about~~ 0.1 pmol/kg/min to 75 pmol/kg/min.
10. (Currently amended) A method for preventing or treating progression of End Stage Renal Disease in a subject having nephropathy comprising  
treating end stage renal disease by administering to an individual in need of such treatment an effective amount of GLP-1, an ~~agonist, analog,~~ analog or derivative ~~thereof~~ thereof, having at least ~~70%~~ 90% amino acid sequence homology to GLP-1. ~~and having at least one action of GLP-1~~
11. (Previously Presented) The method of claim 10 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO:1.
- 12-15. (Canceled)

16. (Previously Presented) The method of claim 10 wherein the compound is administered parenterally.

17. (Currently amended) The method of claim ~~13~~ 10 wherein the compound is administered intravenously in a dose of ~~from about~~ 0.1 pmol/kg/min up to ~~about~~ 10 pmol/kg/min.

18. (Currently amended) The method of claim 1 wherein the compound is administered subcutaneously in a dose of ~~from about~~ 0.1 pmol/kg/min to 75 pmol/kg/min.

19-27. (Canceled)

28. (Currently amended) A method for reducing proteinuria in a patient comprising reducing proteinuria by administering to an individual in need of such treatment an effective amount of a GLP-1, an ~~agonist, analog,~~ analog or derivative ~~thereof thereof,~~ having at least ~~70%~~ 90% amino acid sequence homology to GLP-1. ~~and having at least one action of GLP-1~~

29. (Previously Presented) The method of claim 28 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO: 1.

30-33. (Canceled)

34. (Previously Presented) The method of claim 28 wherein the compound is administered parenterally.

35. (Currently amended) The method of claim ~~34~~ 28 wherein the compound is administered intravenously in a dose of ~~from about~~ 0.1 pmol/kg/min up to ~~about~~ 10 pmol/kg/min.

36. (Currently amended) The method of claim 28 wherein the compound is administered subcutaneously in a dose of ~~from about~~ 0.1 pmol/kg/min to 75 pmol/kg/min.

37. (Currently amended) A method for preventing or slowing progression of glomerulosclerosis in a subject comprising

preventing or slowing progression of glomerulosclerosis by administering to an individual in need of such treatment an effective amount of GLP-1, an ~~agonist, analog,~~ analog or

derivative ~~thereof~~ thereof, having at least ~~70%~~ 90% amino acid sequence homology to GLP-1.  
~~and having at least one action of GLP-1~~

38. (Previously Presented) The method of claim 37 wherein said GLP-1 agonist analog is 90% identical to SEQ ID NO:1.

39-42. (Canceled)

43. (Previously Presented) The method of claim 37 wherein the compound is administered parenterally.

44. (Currently amended) The method of claim 40 wherein the compound is administered intravenously in a dose of ~~from about~~ 0.1 pmol/kg/min ~~up to about~~ 10 pmol/kg/min.

45. (Currently amended) The method of claim 37 wherein the compound is administered subcutaneously in a dose of ~~from about~~ 0.1 pmol/kg/min to 75 pmol/kg/min.

46-51. (Canceled)

52. (Previously Presented) The method of claim 1 wherein said GLP-1 agonist analog is SEQ ID NO: 1.

53. (Previously Presented) The method of claim 10 wherein said GLP-1 agonist analog is SEQ ID NO:1.

54. (Canceled)

55. (Previously Presented) The method of claim 28 wherein said GLP-1 agonist analog is SEQ ID NO:1.

56. (Previously Presented) The method of claim 37 wherein said GLP-1 agonist analog is SEQ ID NO: 1.